Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome. | Novartis has finally given up on iscalimab after deciding that the ...

EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing ...

Eledon Pharmaceuticals has a promising anti-CD40L antibody for organ rejection prevention in transplantation. Learn more ...

Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its ...

The two patients received the treatment as part of a UChicago Medicine pilot study focusing on the use of Eledon's anti CD40 ligand (CD40L) antibody tegoprubart (formerly AT-1501) as an ...

Eledon Pharmaceuticals (ELDN) announced that tegoprubart, the company’s investigational anti-CD40L antibody, was used as a key component of the ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products ...